Roberto Borea MD
@robertoboreamd.bsky.social
Medical Oncologist, PhD student
Focused on lung and breast cancer translational medicine 🧬
Currently working in LB in Malapelle’s Lab 🩸
Focused on lung and breast cancer translational medicine 🧬
Currently working in LB in Malapelle’s Lab 🩸
🚨Excited to represent the @islb.info at #ASCO25!
Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸
@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social
Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸
@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social
May 27, 2025 at 4:07 PM
🚨Excited to represent the @islb.info at #ASCO25!
Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸
@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social
Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸
@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social
#TME in #NSCLC shapes therapy resistance and progression
- a tumor can have two immune niches: rich and poor
- more than immune cells: CAFs, TAMs, DCs, T, NK..
- patient-specific determinants modulate the TME
🔍emerging technologies
www.nature.com/articles/s41...
- a tumor can have two immune niches: rich and poor
- more than immune cells: CAFs, TAMs, DCs, T, NK..
- patient-specific determinants modulate the TME
🔍emerging technologies
www.nature.com/articles/s41...
May 19, 2025 at 9:12 PM
#TME in #NSCLC shapes therapy resistance and progression
- a tumor can have two immune niches: rich and poor
- more than immune cells: CAFs, TAMs, DCs, T, NK..
- patient-specific determinants modulate the TME
🔍emerging technologies
www.nature.com/articles/s41...
- a tumor can have two immune niches: rich and poor
- more than immune cells: CAFs, TAMs, DCs, T, NK..
- patient-specific determinants modulate the TME
🔍emerging technologies
www.nature.com/articles/s41...
📰EGFR-TKI resistance in LUAD isn’t always genetic.
- 39 pts-derived organoids
- 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss.
- Knockout of NKX2-1 → basal-shift + Osim res
- These tumors often lose CDKN2A/B
pbs.twimg.com/media/Gq6QwX...
- 39 pts-derived organoids
- 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss.
- Knockout of NKX2-1 → basal-shift + Osim res
- These tumors often lose CDKN2A/B
pbs.twimg.com/media/Gq6QwX...
May 14, 2025 at 12:44 PM
📰EGFR-TKI resistance in LUAD isn’t always genetic.
- 39 pts-derived organoids
- 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss.
- Knockout of NKX2-1 → basal-shift + Osim res
- These tumors often lose CDKN2A/B
pbs.twimg.com/media/Gq6QwX...
- 39 pts-derived organoids
- 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss.
- Knockout of NKX2-1 → basal-shift + Osim res
- These tumors often lose CDKN2A/B
pbs.twimg.com/media/Gq6QwX...
Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬
LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/
@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social
LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/
@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social
April 21, 2025 at 7:51 PM
Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬
LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/
@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social
LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/
@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social
Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬
Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social
Exciting discussions shaping the future of #lungcancer testing! 📚
Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social
Exciting discussions shaping the future of #lungcancer testing! 📚
April 12, 2025 at 4:32 PM
Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬
Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social
Exciting discussions shaping the future of #lungcancer testing! 📚
Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social
Exciting discussions shaping the future of #lungcancer testing! 📚
Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅
Grateful for the chance to meet with exceptional people 👐
@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
Grateful for the chance to meet with exceptional people 👐
@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
April 11, 2025 at 1:49 AM
Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅
Grateful for the chance to meet with exceptional people 👐
@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
Grateful for the chance to meet with exceptional people 👐
@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
As always, an insightful presentation by @UmbertoMalapelle
➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social
We must continue this path to improve treatment selection!
@islb.info #precisiononcology #lungcancer
⬇️ Key message
➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social
We must continue this path to improve treatment selection!
@islb.info #precisiononcology #lungcancer
⬇️ Key message
March 27, 2025 at 10:15 AM
As always, an insightful presentation by @UmbertoMalapelle
➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social
We must continue this path to improve treatment selection!
@islb.info #precisiononcology #lungcancer
⬇️ Key message
➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social
We must continue this path to improve treatment selection!
@islb.info #precisiononcology #lungcancer
⬇️ Key message
Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights!
@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige
@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige
March 25, 2025 at 9:34 PM
Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights!
@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige
@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige
🚨 Out in @natrevclinoncol.bsky.social
📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view
nature.com/articles/s41...
@christianrolfo.bsky.social @osucccjames.bsky.social
📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view
nature.com/articles/s41...
@christianrolfo.bsky.social @osucccjames.bsky.social
March 17, 2025 at 12:00 PM
🚨 Out in @natrevclinoncol.bsky.social
📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view
nature.com/articles/s41...
@christianrolfo.bsky.social @osucccjames.bsky.social
📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view
nature.com/articles/s41...
@christianrolfo.bsky.social @osucccjames.bsky.social
Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨
It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!
bit.ly/43JzN03
@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!
bit.ly/43JzN03
@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
March 14, 2025 at 3:48 PM
Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨
It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!
bit.ly/43JzN03
@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!
bit.ly/43JzN03
@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology
@rolfolab.bsky.social @oncoalert.bsky.social
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology
@rolfolab.bsky.social @oncoalert.bsky.social
March 13, 2025 at 3:25 PM
Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology
@rolfolab.bsky.social @oncoalert.bsky.social
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology
@rolfolab.bsky.social @oncoalert.bsky.social
Honored to be among the winners of the #TexasLung25 Poster Competition! 🎉 Grateful for the opportunity to share my research and contribute to the future of #lungcancer!
@christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social
➡️ hubs.la/Q03bqnlB0
@christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social
➡️ hubs.la/Q03bqnlB0
March 12, 2025 at 7:35 AM
Honored to be among the winners of the #TexasLung25 Poster Competition! 🎉 Grateful for the opportunity to share my research and contribute to the future of #lungcancer!
@christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social
➡️ hubs.la/Q03bqnlB0
@christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social
➡️ hubs.la/Q03bqnlB0
✨ Insightful presentation by @manelesteller.bsky.social from
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social
March 5, 2025 at 6:32 PM
✨ Insightful presentation by @manelesteller.bsky.social from
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social
Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊
#lungcancer
#myESMO
#DeepDiveLungCancer
@christianrolfo.bsky.social @rolfolab.bsky.social
ow.ly/vbSt50UPrrS
#lungcancer
#myESMO
#DeepDiveLungCancer
@christianrolfo.bsky.social @rolfolab.bsky.social
ow.ly/vbSt50UPrrS
February 3, 2025 at 12:56 PM
Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊
#lungcancer
#myESMO
#DeepDiveLungCancer
@christianrolfo.bsky.social @rolfolab.bsky.social
ow.ly/vbSt50UPrrS
#lungcancer
#myESMO
#DeepDiveLungCancer
@christianrolfo.bsky.social @rolfolab.bsky.social
ow.ly/vbSt50UPrrS
When tissue is the issue!
Great presentation by @christianrolfo.bsky.social
at the XIII Molecular Cytopathology
We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬
@ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1
@MariantoniaNac1
Great presentation by @christianrolfo.bsky.social
at the XIII Molecular Cytopathology
We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬
@ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1
@MariantoniaNac1
December 10, 2024 at 7:12 PM
When tissue is the issue!
Great presentation by @christianrolfo.bsky.social
at the XIII Molecular Cytopathology
We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬
@ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1
@MariantoniaNac1
Great presentation by @christianrolfo.bsky.social
at the XIII Molecular Cytopathology
We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬
@ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1
@MariantoniaNac1
A great initiative by European School of Oncology to share clinical cases among oncologists! I had the possibility to discuss a geriatric breast cancer patients and how to handle specific “frail” situations! 👵🏻
Check the link! 🎯
bit.ly/e-ESO
@unige
Check the link! 🎯
bit.ly/e-ESO
@unige
December 5, 2024 at 10:25 PM
A great initiative by European School of Oncology to share clinical cases among oncologists! I had the possibility to discuss a geriatric breast cancer patients and how to handle specific “frail” situations! 👵🏻
Check the link! 🎯
bit.ly/e-ESO
@unige
Check the link! 🎯
bit.ly/e-ESO
@unige
Honored to had the opportunity to present my experience on CAR-T cells that I did at @unclineberger.bsky.social at a seminar for PhD students at @Dipsanita_UniNa 💪
Such a great class!
@UniGe @UmbertoMalapel1 @christianrolfo.bsky.social @christianrolfo.bsky.social
Such a great class!
@UniGe @UmbertoMalapel1 @christianrolfo.bsky.social @christianrolfo.bsky.social
December 3, 2024 at 6:18 PM
Honored to had the opportunity to present my experience on CAR-T cells that I did at @unclineberger.bsky.social at a seminar for PhD students at @Dipsanita_UniNa 💪
Such a great class!
@UniGe @UmbertoMalapel1 @christianrolfo.bsky.social @christianrolfo.bsky.social
Such a great class!
@UniGe @UmbertoMalapel1 @christianrolfo.bsky.social @christianrolfo.bsky.social
@GianniNigita from @osucccjames.bsky.social @rolfolab.bsky.social presenting the minimal requirements for bioinformatics in analyzing liquid biopsy data at #ISLB24
More complex data —> more power bioinformatics required! 💻🤖
@christianrolfo.bsky.social @UmbertoMalapel1 @isliquidbiopsy
More complex data —> more power bioinformatics required! 💻🤖
@christianrolfo.bsky.social @UmbertoMalapel1 @isliquidbiopsy
November 25, 2024 at 7:22 PM
@GianniNigita from @osucccjames.bsky.social @rolfolab.bsky.social presenting the minimal requirements for bioinformatics in analyzing liquid biopsy data at #ISLB24
More complex data —> more power bioinformatics required! 💻🤖
@christianrolfo.bsky.social @UmbertoMalapel1 @isliquidbiopsy
More complex data —> more power bioinformatics required! 💻🤖
@christianrolfo.bsky.social @UmbertoMalapel1 @isliquidbiopsy
Honored to have @lillian_siu elected president of @AACR at the #ISLB24 meeting talking about HPV ctDNA!
HPV genotyping in plasma may be the future!
Truly inspiring 💪🏻🔥🎯
@isliquidbiopsy
@christianrolfo.bsky.social
@christianrolfo.bsky.social
@UmbertoMalapel1
HPV genotyping in plasma may be the future!
Truly inspiring 💪🏻🔥🎯
@isliquidbiopsy
@christianrolfo.bsky.social
@christianrolfo.bsky.social
@UmbertoMalapel1
November 24, 2024 at 9:10 PM
Honored to have @lillian_siu elected president of @AACR at the #ISLB24 meeting talking about HPV ctDNA!
HPV genotyping in plasma may be the future!
Truly inspiring 💪🏻🔥🎯
@isliquidbiopsy
@christianrolfo.bsky.social
@christianrolfo.bsky.social
@UmbertoMalapel1
HPV genotyping in plasma may be the future!
Truly inspiring 💪🏻🔥🎯
@isliquidbiopsy
@christianrolfo.bsky.social
@christianrolfo.bsky.social
@UmbertoMalapel1
🏆Award session and inspiring Award lectures!
#LuisDiaz #EllenHeltzer #DennisLo
#ISLB24
@isliquidbiopsy @christianrolfo.bsky.social @MJOSESERRANO19
#LuisDiaz #EllenHeltzer #DennisLo
#ISLB24
@isliquidbiopsy @christianrolfo.bsky.social @MJOSESERRANO19
November 24, 2024 at 12:46 AM
🏆Award session and inspiring Award lectures!
#LuisDiaz #EllenHeltzer #DennisLo
#ISLB24
@isliquidbiopsy @christianrolfo.bsky.social @MJOSESERRANO19
#LuisDiaz #EllenHeltzer #DennisLo
#ISLB24
@isliquidbiopsy @christianrolfo.bsky.social @MJOSESERRANO19
🎯 @BrunaPellini just explained to me how their algorithm could help in distinguishing between variants identified via LB “truly/potentially” targetable vs CH-derived across different tumor types
⚡️ Great energy here! @isliquidbiopsy
#ISLB24
⚡️ Great energy here! @isliquidbiopsy
#ISLB24
November 23, 2024 at 11:22 PM
🎯 @BrunaPellini just explained to me how their algorithm could help in distinguishing between variants identified via LB “truly/potentially” targetable vs CH-derived across different tumor types
⚡️ Great energy here! @isliquidbiopsy
#ISLB24
⚡️ Great energy here! @isliquidbiopsy
#ISLB24
❔❓Having expert to discuss key questions in liquid biopsy!
This is #ISLB24
@isliquidbiopsy @christianrolfo.bsky.social
#abhijitPatel #pazVellanki #murryWynes #davidkozono #lucaQuagliata #adamSowalsky
This is #ISLB24
@isliquidbiopsy @christianrolfo.bsky.social
#abhijitPatel #pazVellanki #murryWynes #davidkozono #lucaQuagliata #adamSowalsky
November 23, 2024 at 10:21 PM
❔❓Having expert to discuss key questions in liquid biopsy!
This is #ISLB24
@isliquidbiopsy @christianrolfo.bsky.social
#abhijitPatel #pazVellanki #murryWynes #davidkozono #lucaQuagliata #adamSowalsky
This is #ISLB24
@isliquidbiopsy @christianrolfo.bsky.social
#abhijitPatel #pazVellanki #murryWynes #davidkozono #lucaQuagliata #adamSowalsky
Terrific presentation of @christianrolfo.bsky.social from @OSUCCC_James on tumor fraction detection and calculation in cfDNA! 🧬
—> we must implement cfDNA fraction analysis to improve the comprehension of LB
#ISLB24
@internationalsocietyofliquidbiopsy
@UmbertoMalapel1 @stoverlab.bsky.social
—> we must implement cfDNA fraction analysis to improve the comprehension of LB
#ISLB24
@internationalsocietyofliquidbiopsy
@UmbertoMalapel1 @stoverlab.bsky.social
November 23, 2024 at 5:56 PM
Terrific presentation of @christianrolfo.bsky.social from @OSUCCC_James on tumor fraction detection and calculation in cfDNA! 🧬
—> we must implement cfDNA fraction analysis to improve the comprehension of LB
#ISLB24
@internationalsocietyofliquidbiopsy
@UmbertoMalapel1 @stoverlab.bsky.social
—> we must implement cfDNA fraction analysis to improve the comprehension of LB
#ISLB24
@internationalsocietyofliquidbiopsy
@UmbertoMalapel1 @stoverlab.bsky.social
Great presentation from @natashaleighl from @pmargaretcancercenter on the usage of molecular testing in cancer patients!
🥵 Hot topics:
- timing ⏱️
- patient point of view 🫵
- type of test 🤷🏻♀️
- cost 💰
#ISLB24
🥵 Hot topics:
- timing ⏱️
- patient point of view 🫵
- type of test 🤷🏻♀️
- cost 💰
#ISLB24
November 23, 2024 at 5:30 PM
Great presentation from @natashaleighl from @pmargaretcancercenter on the usage of molecular testing in cancer patients!
🥵 Hot topics:
- timing ⏱️
- patient point of view 🫵
- type of test 🤷🏻♀️
- cost 💰
#ISLB24
🥵 Hot topics:
- timing ⏱️
- patient point of view 🫵
- type of test 🤷🏻♀️
- cost 💰
#ISLB24
LB 🩸 isn’t only for medical oncologist!
@aadel_chaudhuri from @MayoClinic is sharing data on the use of LB MRD during and after radiotherapy treatment with great results in predicting patient outcome!
#ISLB24
@christianrolfo.bsky.social @rolfolab.bsky.social
@isliquidbiopsy
@aadel_chaudhuri from @MayoClinic is sharing data on the use of LB MRD during and after radiotherapy treatment with great results in predicting patient outcome!
#ISLB24
@christianrolfo.bsky.social @rolfolab.bsky.social
@isliquidbiopsy
November 23, 2024 at 5:01 PM
LB 🩸 isn’t only for medical oncologist!
@aadel_chaudhuri from @MayoClinic is sharing data on the use of LB MRD during and after radiotherapy treatment with great results in predicting patient outcome!
#ISLB24
@christianrolfo.bsky.social @rolfolab.bsky.social
@isliquidbiopsy
@aadel_chaudhuri from @MayoClinic is sharing data on the use of LB MRD during and after radiotherapy treatment with great results in predicting patient outcome!
#ISLB24
@christianrolfo.bsky.social @rolfolab.bsky.social
@isliquidbiopsy